Ambirix market seen growing as hepatitis prevention spending rises

The Business Research Company says the Ambirix vaccine market is set for steady expansion through 2035, driven by hepatitis cases, wider pediatric vaccination efforts, and higher healthcare spending. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Ambirix is positioned to benefit from rising demand for hepatitis prevention, especially in children. - The market outlook matters because the vaccine supports public health goals tied to reducing hepatitis A and B infections. - Growth in vaccine access and government immunization programs could expand demand in both developed and developing markets.

What happened: - The Business Research Company released a market report on Ambirix with a 2026 base year and a global forecast through 2035. - The report says the Ambirix market is gaining traction as global efforts to combat hepatitis infections intensify. - North America held the largest share of the global Ambirix market in 2025. - Asia-Pacific is projected to be the fastest-growing regional market during the forecast period.

The details: - Ambirix is a combined vaccine that protects against hepatitis A and B. - The vaccine contains inactivated hepatitis A virus and purified hepatitis B surface antigen. - Ambirix is mainly prescribed for children ages 1 to 15 and is given in two doses over six months. - The vaccine is designed to provide long-term protection and reduce the risk of serious liver disease linked to hepatitis A and B. - Historical market growth has been supported by the global burden of hepatitis, childhood vaccine schedules, public health policies, early approval of combination vaccines, and school-based vaccination initiatives. - Future growth is expected to come from broader pediatric vaccine coverage, improved access in developing regions, long-lasting immunity, higher public health funding, and global hepatitis elimination goals. - The report highlights several trends, including combination vaccines, broader pediatric immunization programs, greater focus on hepatitis prevention, better compliance from fewer doses, and government-backed vaccination campaigns. - Rising hepatitis infections are a major market driver. - The CDC reported 17,650 new chronic hepatitis B cases across 44 states and the District of Columbia in 2023, equal to 6.1 cases per 100,000 people. - Poor sanitation, limited vaccination coverage, and population mobility continue to support hepatitis A and B transmission. - Increased awareness of pediatric immunization is also supporting demand for Ambirix. - The report cites a July 2024 WHO update showing global first-dose HPV vaccine coverage for girls rose to 27% in 2023 from 20% in 2022. - Healthcare spending growth is another support for the market. - The UK Office for National Statistics reported a 5.6% rise in nominal healthcare expenditure between 2022 and 2023, after 0.9% growth in the prior year. - Long-term health and social care spending in the UK rose 2.8% in real terms during 2022. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The company also says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, and updated graphics and tables.

Between the lines: - The market story is less about a single product and more about structural public health shifts: more vaccination coverage, more government support, and more spending on prevention. - Ambirix’s two-dose schedule may help adoption where adherence to multi-shot vaccine regimens is a challenge. - North America’s lead suggests mature infrastructure still drives revenue, while Asia-Pacific’s faster growth points to rising unmet need and expanding access.

What's next: - The market will likely track hepatitis elimination efforts, pediatric immunization expansion, and public funding decisions through 2035. - Vaccine makers and distributors may see the most opportunity in regions improving access and coverage. - The full report is available here and a sample is available here.